Biomerica Inc. (NASDAQ: BMRA) has appointed Scott Madel as Chief Commercial Officer to accelerate the commercialization of its inFoods IBS diagnostic test, the company announced. Madel brings more than two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and payer strategy to drive revenue growth for the innovative gastrointestinal diagnostic solution.
Clinical Leadership Experience
Madel most recently served as President of Boston Heart Diagnostics, where he led a successful organizational turnaround and introduced novel cardiovascular testing technologies across diverse payer channels, significantly boosting revenue through personalized testing solutions. Prior to Boston Heart, he served as CEO of BioHealth Diagnostics and CEO of Genova Diagnostics Europe, helping grow Genova to over $100 million in annual revenue and launching diagnostics for chronic disease across 45 countries.
His early career included frontline field sales roles at Novartis Pharmaceuticals and Merck, providing insight into the full commercial lifecycle. Madel holds a Bachelor of Science in Medical Microbiology and Immunology from the University of Wisconsin–Madison and is currently completing his MBA from Northeastern University.
Strategic Commercial Focus
In his new role, Madel will expand and accelerate commercialization and revenue growth for inFoods IBS by focusing on strategic partnerships, developing a robust payer strategy, achieving third-party payer reimbursement, and scaling domestic and global provider engagement and brand recognition.
"I'm excited to join Biomerica and champion the growth of inFoods IBS," said Madel. "This innovative solution has the potential to substantially improve the quality of life for millions of patients suffering from chronic GI conditions. I look forward to working alongside the team to bring this clinically proven breakthrough technology to practitioners and patients worldwide—delivering better outcomes, improving patient experience, and reducing the cost to treat this chronic condition."
Clinical Evidence and Market Potential
The inFoods IBS test is a diagnostic-guided therapy that identifies patient-specific food triggers responsible for symptoms such as abdominal pain, bloating, diarrhea, and constipation. Using a simple finger-stick blood sample, the test enables physicians to recommend targeted dietary changes tailored to the patient's immune response, offering a non-pharmaceutical, precision-based approach to symptom relief.
A multicenter, double-blinded placebo-controlled clinical study on the inFoods IBS test was published in the June issue of Gastroenterology, the top peer-reviewed GI journal. As the largest study of its kind, it demonstrated statistically significant outcomes with 59.6% of patients in the treatment group achieving the FDA's endpoint for abdominal pain reduction, compared to 42.2% in the control group.
The results were particularly striking in specific IBS subtypes. Among IBS-C patients, 67.1% of patients in the treatment group achieved the endpoint versus 35.8% in the control group. Among IBS-M patients, 66% of patients in the treatment group achieved the endpoint compared to 29.5% in the control group.
Addressing Unmet Medical Need
These results highlight inFoods IBS as the only targeted therapy to demonstrate efficacy specifically in IBS-M patients, a subgroup historically underserved by existing treatments. The study was conducted at leading U.S. institutions including Cleveland Clinic, Mayo Clinic, University of Michigan, and Beth Israel Deaconess Medical Center.
"Scott's rich commercial experience, knowledge and deep industry relationships should dramatically increase revenues from inFoods IBS across markets," said Zack Irani, CEO of Biomerica. "We're confident his strategic insights will drive our domestic launch and future international business."
The inFoods IBS test is currently available as a Laboratory Developed Test (LDT) used within a single laboratory that is certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high-complexity testing. Biomerica focuses primarily on gastrointestinal and inflammatory diseases and has multiple diagnostic and therapeutic products in development.
